De-escalating antiplatelet therapy in patients with acute coronary syndrome

Abstract

Dual antiplatelet therapy (DAPT), combining aspirin and a P2Y12 receptor inhibitor, is the basis of acute coronary syndrome (ACS) treatment, demonstrating efficacy in reducing ischemic complications while being linked to increased bleeding. Recent interest has emerged in bleeding reduction strategies, specifically de-escalation strategies involving P2Y12 inhibitor potency and dosage modulation that can be achieved in two different ways: the unguided de-escalation, where P2Y12 inhibitors are adjusted based on clinical judgment, and the guided de-escalation, incorporating genetic or platelet function tests to tailor the therapy. Several randomized controlled trials (RCTs) demonstrated that both unguided and guided de-escalation strategies can reduce bleeding without compromising ischemic outcomes. However, some gaps in evidence are still present and further investigation is needed. Ongoing and upcoming RCTs aim to address uncertainties, including direct comparisons between de-escalation strategies, optimal timing for intervention, and personalized approaches guided by genetic testing. Furthermore, the review emphasizes the need for standardization in implementing de-escalation strategies in routine clinical practice.

Keywords

Dual antiplatelet therapy / P2Y12 inhibitors / acute coronary syndrome / percutaneous coronary intervention / de-escalation / bleeding

References

[1] Capodanno D,Levine GN,Angiolillo DJ.ACC/AHA versus ESC guidelines on dual antiplatelet therapy.J Am Coll Cardiol2018;72:2915-31

[2] Cao D,Chiarito M,Mehran R.Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey.Eur Heart J2021;42:339-51

[3] Costa F,Valgimigli M.Dual antiplatelet therapy duration: reconciling the inconsistencies.Drugs2017;77:1733-54

[4] Giustino G.Characterization of the individual patient risk after percutaneous coronary intervention.JACC Cardiovasc Interv2019;12:831-4

[5] Patrono C,Baigent C.Antiplatelet agents for the treatment and prevention of coronary atherothrombosis.J Am Coll Cardiol2017;70:1760-76

[6] Cavender MA.Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (cangrelor versus standard therapy to achieve optimal management of platelet inhibition).Circulation2016;134:723-33 PMCID:PMC5006794

[7] Bhatt DL,Mahaffey KW.Effect of platelet inhibition with cangrelor during PCI on ischemic events.N Engl J Med2013;368:1303-13

[8] Angiolillo DA,Collet JP,O’Donoghue MO.Antiplatelet therapy after percutaneous coronary intervention.EuroIntervention2022;17:e1371-96 PMCID:PMC9896394

[9] Collet JP,Byrne RA.Case-based implementation of the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease.Eur Heart J2018;39:e1-33

[10] Byrne RA,Coughlan JJ.2023 ESC Guidelines for the management of acute coronary syndromes.Eur Heart J2024;13:55-161

[11] Valgimigli M,Lokhnygina Y.Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial.Eur Heart J2017;38:804-10 PMCID:PMC5837470

[12] Capodanno D,Krucoff MW.Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium.Circulation2023;147:1933-44

[13] Galli M,Andreotti F.Bleeding complications in patients undergoing percutaneous coronary intervention.Rev Cardiovasc Med2022;23:286 PMCID:PMC11266963

[14] Patrono C.Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease.Eur Heart J2024;45:2362-76 PMCID:PMC11242460

[15] Sibbing D,Alexopoulos D.Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention.JACC Cardiovasc Interv2019;12:1521-37

[16] Hwang D,Park KW.Prasugrel dose de-escalation therapy after complex percutaneous coronary intervention in patients with acute coronary syndrome: a post hoc analysis from the HOST-REDUCE-POLYTECH-ACS trial.JAMA Cardiol2022;7:418 PMCID:PMC8908232

[17] Galli M.De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?.Front Cardiovasc Med2022;9:975969 PMCID:PMC9452742

[18] Cuisset T,Quilici J.Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.Eur Heart J2017;38:3070-8

[19] Kim HS,Hwang D.Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.The Lancet2020;396:1079-89

[20] Kim CJ,Kim MC.Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.The Lancet2021;398:1305-16

[21] Tavenier AH,Chiarito M.Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.Eur Heart J2022;8:492-502

[22] Piccolo R,Avvedimento M.Ticagrelor 60 versus 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial.Eur Heart J2024;pvae054

[23] Galli M,Rollini F.Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.Trends Cardiovasc Med2023;33:133-8

[24] Gurbel PA,Shuldiner AR.Genotyping.J Am Coll Cardiol2010;56:112-6

[25] Capodanno D,Lennon RJ.ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI Trial.J Am Heart Assoc2022;11:e024156 PMCID:PMC9245815

[26] Cayla G,Silvain J.Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.The Lancet2016;388:2015-22

[27] Sibbing D,Jacobshagen C.Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.The Lancet2017;390:1747-57

[28] Claassens DMF,Bergmeijer TO.A genotype-guided strategy for Oral P2Y 12 inhibitors in primary PCI.N Engl J Med2019;381:1621-31

[29] Galli M,Capodanno D.Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.The Lancet2021;397:1470-83

[30] Galli M,Franchi F.Comparative effects of guided versus potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.Eur Heart J2022;43:959-67 PMCID:PMC9127738

[31] De Luca G,Camaro C.Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial).EuroIntervention2019;15:e990-8

[32] Hahn JY,Oh JH.6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.The Lancet2018;391:1274-84

[33] Kedhi E,Van Der Ent M.Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.BMJ2018;k3793 PMCID:PMC6167608

[34] Costa F,Branca M.Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.Eur Heart J2023;44:954-68

[35] Collet JP,Barbato E.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J2021;42:1289-367

[36] Capodanno D,Bhatt DL.P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.Nat Rev Cardiol2022;19:829-44

[37] Galli M,Andreotti F,Angiolillo DJ.Safety and efficacy of P2Y 12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions.Expert Opin Drug Saf2021;20:9-21

[38] Watanabe H,Natsuaki M.Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial.JAMA Cardiol2022;7:407 PMCID:PMC8892373

[39] Kim BK,Cho YH.Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial.JAMA2020;323:2407 PMCID:PMC7298605

[40] Hong SJ,Suh Y.Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial.Circulation2024;149:562-73

[41] De Caterina R,Andreotti F.Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.Eur Heart J2022;43:3512-27

[42] Laudani C,Occhipinti G.Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes.JACC Cardiovasc Interv2022;15:268-77

[43] Kuno T,Shoji S.Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis.Circ Cardiovasc Interv2023;16:e013242

[44] De Filippo O,Bruno F.De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.BMJ Evid-Based Med2024;29:171-86

[45] Costa F,James S.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.The Lancet2017;389:1025-34